By Dean Seal
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy.
The stock was up 9.5% at 1.28 in premarket trading. Shares had fallen 25% year-to-date when the market closed last week.
The clinical-stage biopharma company said Monday that the Food and Drug Administration has lifted a clinical hold on ENTR-601-44 and authorized a Phase 1b clinical study of it as a potential treatment for Duchenne muscular dystrophy in certain adult patients.
"Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance," Chief Executive Dipal Doshi said.
Entrada plans to launch enrollment for the study in the first half of 2026.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 24, 2025 07:32 ET (12:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.